Antisense modulation of apolipoprotein B expression

Details for Australian Patent Application No. 2005272912 (hide)

International Classifications

Event Publications

29 March 2007 PCT application entered the National Phase

PCT publication WO2006/020676 Priority application(s): WO2006/020676

16 July 2009 Section 223 Application Allowed

Isis Pharmaceuticals, Inc. The time in which to request examination has been extended to 02 Jul 2009. Address for service in Australia - Wrays Ground Floor 56 Ord Street West Perth WA 6005 2007

16 July 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

20 May 2010 Assignment before Grant

Isis Pharmaceuticals, Inc. The application has been assigned to Genzyme Corporation 2007

2 February 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.